ASCO 2026: Fasting before and after chemo may help improve treatment response for some people with ovarian cancer
A new study based in Italy found that fasting before and after chemotherapy sessions, when…
Browsing: ASCO
ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate cancer
Results from the phase 2 ARACOG study, the first direct comparison of the cognitive effects…
ASCO 2026: Trial tests virus-immunotherapy combination for neuroendocrine tumours
A phase I clinical trial is testing whether a tumour-targeting virus can help immunotherapy work…
ASCO 2026: New AI tool may help personalise multiple myeloma treatment
An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are…
ASCO GU 2026: Enfortumab vedotin pembrolizumab combo may reduce risk of recurrence for some MIBC cases
Results from the phase 3 KEYNOTE-B15 clinical trial found that the combination of the targeted…
ASCO GU 2026: Cancer’s clues in the bloodstream reveal the role androgen receptor alterations play in metastatic prostate cancer
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under…
ASCO GU 2026: Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery
A new study led by UCLA Health Jonsson Comprehensive Cancer Centre investigators suggests that adding hormone therapy…
ASCO GI 2026: Key gastrointestinal cancer trials shaping practice across CRC, upper GI and hepatobiliary disease
New data presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) highlight continued momentum…
ASCO GI 2026: Zanidatamab and chemotherapy can slow cancer growth, extend survival in some people with gastroesophageal adenocarcinoma
Results from a new phase 3 study found that for people with human epidermal growth…
ASCO 2025 Special Part 2! S3E5 The Oncology Journal Club
Welcome to Part 2 of the 2025 ASCO ASM Special of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson to unpack practice changing presentations from Chicago.